VISIONBLUE Drug Patent Profile

Which patents cover Visionblue, and what generic alternatives are available?

Visionblue is a drug marketed by Dorc and is included in one NDA.

The generic ingredient in VISIONBLUE is trypan blue. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the trypan blue profile page.

Summary for VISIONBLUE

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	40
What excipients (inactive ingredients) are in VISIONBLUE?	VISIONBLUE excipients list
DailyMed Link:	VISIONBLUE at DailyMed

Pharmacology for VISIONBLUE

Drug Class	Diagnostic Dye
Mechanism of Action	Dyes

US Patents and Regulatory Information for VISIONBLUE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Dorc	VISIONBLUE	trypan blue	SOLUTION;OPHTHALMIC	021670-001	Dec 16, 2004		RX	Yes	Yes

Expired US Patents for VISIONBLUE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Dorc	VISIONBLUE	trypan blue	SOLUTION;OPHTHALMIC	021670-001	Dec 16, 2004	6,367,480
Dorc	VISIONBLUE	trypan blue	SOLUTION;OPHTHALMIC	021670-001	Dec 16, 2004	6,720,314

International Patents for VISIONBLUE

See the table below for patents covering VISIONBLUE around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	69905355
Australia	3853699
European Patent Office	0974367

VISIONBLUE Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for VISIONBLUE

Introduction

VISIONBLUE, also known as Trypan Blue, is an ophthalmic solution used primarily as a surgical aid. Here, we will delve into the market dynamics and financial trajectory of this drug, highlighting key factors that influence its market presence.

Market Overview

VISIONBLUE is marketed by the Dutch Ophthalmic Research Center International BV and is classified under the ATC code S01KX, which categorizes it as a surgical aid[3].

Demand and Supply

The demand for VISIONBLUE has seen an increase, which was evident from a reported shortage in 2021-2022. The shortage was attributed to an increased demand for the drug, indicating a strong market need for this ophthalmic solution[3].

Market Segment

VISIONBLUE falls under the broader category of ophthalmic drugs, which is a growing market driven by the increasing prevalence of eye-related disorders. The U.S. ophthalmic drugs market, for example, was estimated at USD 15.53 billion in 2023 and is expected to grow at a CAGR of 7.4% from 2024 to 2030[1].

Financial Performance

While specific financial data for VISIONBLUE is not readily available, its market performance can be inferred from the broader ophthalmic drugs market. The ophthalmic drugs market is driven by significant revenue from prescription drugs, with branded drugs holding the largest share. The approval and launch of new ophthalmic drugs, such as EYLEA and Vabysmo, have significantly contributed to the market's financial growth[1][4].

Revenue Streams

The revenue for VISIONBLUE would primarily come from its use in ophthalmic surgeries. Given its classification as a surgical aid, it is likely that the revenue is generated through sales to hospitals, surgical centers, and ophthalmic clinics.

Competitive Landscape

The ophthalmic drugs market is highly competitive, with major players like Regeneron Pharmaceuticals, Bayer, and Bausch + Lomb dominating the scene. While VISIONBLUE is a niche product, its market presence is influenced by the overall competitive dynamics of the ophthalmic drugs market. Innovations such as anti-VEGF agents and bispecific antibodies (e.g., Faricimab) are driving market growth and competition[1][4].

Regulatory Environment

VISIONBLUE is marketed and its market status is closely tied to regulatory approvals and compliance. The drug has been approved and is currently marketed, but any changes in regulatory requirements or approvals could impact its financial trajectory[3].

Future Outlook

Given the increasing demand for ophthalmic solutions and the growing prevalence of eye-related disorders, the market for VISIONBLUE is expected to remain stable. However, the financial performance will depend on factors such as competition from new products, pricing strategies, and regulatory environments.

Key Takeaways

• Market Demand: Increased demand for VISIONBLUE has led to reported shortages.
• Market Segment: Part of the broader and growing ophthalmic drugs market.
• Financial Performance: Influenced by the overall ophthalmic drugs market, with significant revenue from prescription and branded drugs.
• Revenue Streams: Primarily generated through sales to hospitals and ophthalmic clinics.
• Competitive Landscape: Highly competitive market with major players driving innovation and competition.
• Regulatory Environment: Closely tied to regulatory approvals and compliance.

FAQs

1. What is VISIONBLUE used for? VISIONBLUE, or Trypan Blue, is used as a surgical aid in ophthalmic procedures.

2. Why was there a shortage of VISIONBLUE in 2021-2022? The shortage was due to an increased demand for the drug.

3. How does VISIONBLUE fit into the broader ophthalmic drugs market? VISIONBLUE is part of the growing ophthalmic drugs market, which is driven by the increasing prevalence of eye-related disorders.

4. What are the key factors influencing the financial performance of VISIONBLUE? The financial performance is influenced by the overall ophthalmic drugs market, competition from new products, pricing strategies, and regulatory environments.

5. What is the outlook for VISIONBLUE in the future? The market for VISIONBLUE is expected to remain stable due to the increasing demand for ophthalmic solutions and the growing prevalence of eye-related disorders.

Sources

1. Grand View Research: U.S. Ophthalmic Drugs Market Size | Industry Report, 2030
2. Vision Blue Resources: Vision Blue Resources Completes US$650m Fundraising
3. Drug Shortage Report: Drug Shortage Report for VISIONBLUE
4. Biochempeg: Insights into Ophthalmic Drug Innovations and Market Trends